查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1672126

全球慢性特发性便秘治疗市场研究报告-产业分析、规模、份额、成长、趋势和预测 2025 年至 2033 年

Global Chronic Idiopathic Constipation Treatment Market Research Report- Industry Analysis, Size, Share, Growth, Trends and Forecast 2025 to 2033
出版日期: | 出版商: Value Market Research | 英文 158 Pages | 商品交期: 最快1-2个工作天内

价格

全球慢性特发性便秘治疗市场规模预计将从 2024 年的 36.3 亿美元增长到 2033 年的 67.7 亿美元，在 2026 年至 2033 年的预测期内呈现 7.17% 的强劲年复合成长率(CAGR)。

随着胃肠道疾病的盛行率不断上升以及人们对可用治疗方案的认识不断提高，慢性特发性便秘治疗市场有望大幅成长。慢性特发性便秘（CIC）是一种常见疾病，其特征是排便不频繁和排便困难，会严重影响患者的生活品质。随着医疗保健提供者寻求改善患者治疗结果并加强对 CIC 的管理，对有效疗法（包括泻药、处方药和饮食干预）的需求预计将上升，从而使该市场实现强劲扩张。

此外，CIC 治疗方案的进步正在推动市场创新。鸟苷酸环化酶-C激动剂和血清素受体激动剂等新型药物的开发扩大了 CIC 的治疗前景，为患者提供了更有效、更有针对性的治疗选择。这些创新不仅改善了肠道功能，也解决了便秘的根本机制，并提高了患者的整体满意度。随着研究不断探索新的疗法和联合疗法，慢性特发性便秘治疗市场可能会进一步扩大，这得益于改善患者护理和生活品质的前景。

此外，人们对生活方式的改变和预防保健的日益重视正在塑造慢性特发性便秘的治疗模式。随着医疗保健提供者越来越认识到饮食、补水和体力活动在管理 CIC 中的重要性，对教育资源和支持计划的需求可能会增加。这种积极主动的方法不仅使患者能够控制自己的病情，而且还促进了患者和医疗保健提供者之间的合作关係。随着市场不断发展，创新疗法、病患教育和对生活方式介入的关注将在推动其未来成长中发挥关键作用。

我们的报告经过精心製作，为客户提供有关各个行业和市场的全面且可操作的见解。每份报告都包含几个关键部分，以确保彻底了解市场格局：

市场概览：市场的详细介绍，包括定义、分类和行业现状概述。

市场动态：深入分析影响市场成长的关键驱动因素、限制因素、机会与挑战。本节探讨技术进步、监管变化和新兴趋势等因素。

細項分析：根据产品类型、应用、最终用户和地理位置等标准将市场细分为不同的细分市场。该分析强调了每个部分的表现和潜力。

竞争格局：对主要市场参与者的全面评估，包括其市场份额、产品组合、策略倡议和财务表现。本节深入介绍领先公司的竞争动态和关键策略。

市场预测：根据历史资料和当前市场状况，预测特定时期内的市场规模和成长趋势。这包括定量分析和图形表示来说明未来的市场轨迹。

区域分析：评估不同地理区域的市场表现，确定关键市场和区域趋势。这有助于了解区域市场动态和机会。

新兴趋势与机会：识别当前和新兴的市场趋势、技术创新和潜在投资领域。本节提供未来市场发展和成长前景的见解。

目录

第 1 章：前言

  • 报告描述
    • 客观的
    • 目标受众
    • 独特的销售主张 (USP) 和产品
  • 研究范围
  • 研究方法
    • 市场研究流程
    • 市场研究方法

第 2 章：执行摘要

  • 市集亮点
  • 全球市场概况

第 3 章：慢性特发性便秘治疗产业分析

  • 简介 - 市场动态
  • 市场驱动因素
  • 市场限制
  • 机会
  • 产业趋势
  • 波特五力分析
  • 市场吸引力分析
    • 按类型分析市场吸引力
    • 按治疗类型进行的市场吸引力分析
    • 依治疗类型进行市场吸引力分析
    • 药品市场吸引力分析
    • 按给药途径进行的市场吸引力分析
    • 最终用户的市场吸引力分析
    • 按配销通路进行的市场吸引力分析
    • 市场吸引力分析：按地区

第四章：价值链分析

  • 价值链分析
  • 原料分析
    • 原料清单
    • 原料製造商清单
    • 主要原物料价格走势
  • 潜在买家名单
  • 行销管道
    • 直效行销
    • 间接行销
    • 行销通路发展趋势

第 5 章：全球慢性特发性便秘治疗市场分析：按类型

  • 按类型概览
  • 按类型进行的历史和预测资料分析
  • 正常传输性便秘
  • 慢速传输型便秘
  • 其他的

第 6 章：全球慢性特发性便秘治疗市场分析：依治疗类型

  • 按治疗类型概述
  • 按治疗类型进行的历史和预测数据分析
  • 药物治疗
  • 非药物治疗

第 7 章：全球慢性特发性便秘治疗市场分析：依治疗类型

  • 按治疗类型概述
  • 按治疗类型进行的历史和预测数据分析
  • 药物
  • 手术

第 8 章：全球慢性特发性便秘治疗市场分析：按药物

  • 药物概览
  • 按药物进行的历史和预测数据分析
  • 5-羟色胺-4（5-HT4）受体激动剂
  • 鸟苷酸环化酶-C 激动剂
  • 泻药
  • 兴奋剂
  • 其他的

第 9 章：全球慢性特发性便秘治疗市场分析：依给药途径

  • 依给药途径概述
  • 按给药途径进行的历史和预测数据分析
  • 口服
  • 注射剂

第 10 章：全球慢性特发性便秘治疗市场分析：依最终用户

  • 最终用户概览
  • 最终用户的历史和预测数据分析
  • 医院
  • 居家护理
  • 专科诊所
  • 其他的

第 11 章：全球慢性特发性便秘治疗市场分析：按通路

  • 按配销通路概览
  • 按配销通路进行的历史和预测资料分析
  • 医院药房
  • 零售药局
  • 其他的

第 12 章：全球慢性特发性便秘治疗市场分析：按地区划分

  • 区域展望
  • 介绍
  • 北美销售分析
    • 概述、历史和预测数据销售分析
    • 北美各细分市场销售分析
    • 北美各国销售分析
    • 美国销售分析
    • 加拿大销售分析
    • 墨西哥销售分析
  • 欧洲销售分析
    • 概述、历史和预测数据销售分析
    • 欧洲各细分市场销售分析
    • 欧洲各国销售分析
    • 英国销售分析
    • 法国销售分析
    • 德国销售分析
    • 义大利销售分析
    • 俄罗斯销售分析
    • 欧洲其他地区销售分析
  • 亚太地区销售分析
    • 概述、历史和预测数据销售分析
    • 亚太地区分部销售分析
    • 亚太地区国家销售分析
    • 中国销售分析
    • 印度销售分析
    • 日本销售分析
    • 韩国销售分析
    • 澳洲销售分析
    • 东南亚销售分析
    • 亚太地区其他地区销售分析
  • 拉丁美洲销售分析
    • 概述、历史和预测数据销售分析
    • 拉丁美洲各细分市场销售分析
    • 拉丁美洲各国销售分析
    • 巴西销售分析
    • 阿根廷销售分析
    • 秘鲁销售分析
    • 智利销售分析
    • 拉丁美洲其他地区销售分析
  • 中东和非洲销售分析
    • 概述、历史和预测数据销售分析
    • 中东和非洲分部销售分析
    • 中东和非洲国家销售分析
    • 沙乌地阿拉伯销售分析
    • 阿联酋销售分析
    • 以色列销售分析
    • 南非销售分析
    • 中东和非洲其他地区销售分析

第 13 章：慢性特发性便秘治疗公司的竞争格局

  • 慢性特发性便秘治疗市场竞争
  • 伙伴关係/合作/协议
  • 合併与收购
  • 新产品发布
  • 其他进展

第 14 章：公司简介

  • 顶级公司市占率分析
  • 市场集中度
  • ALLERGAN
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Mallinckrodt Plc
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Synergy Pharmaceuticals Inc
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Shandong Luoxin Pharmaceutical Group Stock Co. Ltd
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Takeda Pharmaceutical Company Limited
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Sanofi
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Zydus Cadila
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Boehringer Ingelheim International GmbH
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Shreya Life Sciences Pvt Ltd
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Abbott
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • GSK Plc
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Troikaa Pharmaceuticals Ltd
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Lupin
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • East West Pharma
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Ironwood Pharmaceuticals Inc
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态

注意 - 在公司简介中，财务细节和最新发展取决于可用性，对于私人公司，可能不予涵盖

Product Code: VMR11214173

Global Chronic Idiopathic Constipation Treatment Market size is anticipated to grow from USD 3.63 Billion in 2024 to USD 6.77 Billion by 2033, showcasing a robust Compound Annual Growth Rate (CAGR) of 7.17% during the forecast period of 2026 to 2033.

The chronic idiopathic constipation treatment market is poised for significant growth, driven by the increasing prevalence of gastrointestinal disorders and the rising awareness of available treatment options. Chronic idiopathic constipation (CIC) is a common condition characterized by infrequent bowel movements and difficulty in passing stools, which can significantly impact patients' quality of life. As healthcare providers seek to improve patient outcomes and enhance the management of CIC, the demand for effective therapies, including laxatives, prescription medications, and dietary interventions, is expected to rise, positioning this market for robust expansion.

Moreover, advancements in treatment options for CIC are driving innovation within the market. The development of novel pharmacological agents, such as guanylate cyclase-C agonists and serotonin receptor agonists, has expanded the therapeutic landscape for CIC, offering patients more effective and targeted treatment options. These innovations not only improve bowel function but also address the underlying mechanisms of constipation, enhancing overall patient satisfaction. As research continues to explore new therapies and combination treatments, the chronic idiopathic constipation treatment market is likely to expand further, driven by the promise of improved patient care and quality of life.

Additionally, the growing emphasis on lifestyle modifications and preventive care is shaping the chronic idiopathic constipation treatment landscape. As healthcare providers increasingly recognize the importance of diet, hydration, and physical activity in managing CIC, the demand for educational resources and support programs is likely to increase. This proactive approach not only empowers patients to take control of their condition but also fosters a collaborative relationship between patients and healthcare providers. As the market continues to evolve, the combination of innovative therapies, patient education, and a focus on lifestyle interventions will play a crucial role in driving its future growth.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

SEGMENTATION COVERED IN THE REPORT

By Type

  • Normal-transit constipation
  • Slow-transit constipation
  • Others

By Therapy Type

  • Pharmacological Therapy
  • Non-pharmacological Therapy

By Treatment Type

  • Medication
  • Surgery

By Drugs

  • Serotonin-4 (5-Ht4) Receptor Agonist
  • Guanylate Cyclase-C Agonist
  • Laxatives
  • Stimulants
  • Others

By Route of Administration

  • Oral
  • Injectable

By End-Users

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others
  • COMPANIES PROFILED
  • ALLERGAN
  • Mallinckrodt plc
  • Synergy Pharmaceuticals Inc
  • Shandong Luoxin Pharmaceutical Group Stock Co. Ltd
  • Takeda Pharmaceutical Company Limited
  • Sanofi
  • Zydus Cadila
  • Boehringer Ingelheim International GmbH
  • Shreya Life Sciences Pvt Ltd
  • Abbott
  • GSK plc
  • Troikaa Pharmaceuticals Ltd
  • Lupin
  • East West Pharma
  • Ironwood Pharmaceuticals Inc.
  • The above list can be customized.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Report Description
    • 1.1.1 Objective
    • 1.1.2 Target Audience
    • 1.1.3 Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1 Market Research Process
    • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3. CHRONIC IDIOPATHIC CONSTIPATION TREATMENT INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porters Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Type
    • 3.7.2 Market Attractiveness Analysis By Therapy Type
    • 3.7.3 Market Attractiveness Analysis By Treatment Type
    • 3.7.4 Market Attractiveness Analysis By Drugs
    • 3.7.5 Market Attractiveness Analysis By Route of Administration
    • 3.7.6 Market Attractiveness Analysis By End-Users
    • 3.7.7 Market Attractiveness Analysis By Distribution Channel
    • 3.7.8 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1 List of Raw Materials
    • 4.2.2 Raw Material Manufactures List
    • 4.2.3 Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1 Direct Marketing
    • 4.4.2 Indirect Marketing
    • 4.4.3 Marketing Channel Development Trend

5. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION TREATMENT MARKET ANALYSIS BY TYPE

  • 5.1. Overview By Type
  • 5.2. Historical and Forecast Data Analysis By Type
  • 5.3. Normal-transit constipation Historic and Forecast Sales By Regions
  • 5.4. Slow-transit constipation Historic and Forecast Sales By Regions
  • 5.5. Others Historic and Forecast Sales By Regions

6. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION TREATMENT MARKET ANALYSIS BY THERAPY TYPE

  • 6.1. Overview By Therapy Type
  • 6.2. Historical and Forecast Data Analysis By Therapy Type
  • 6.3. Pharmacological Therapy Historic and Forecast Sales By Regions
  • 6.4. Non-pharmacological Therapy Historic and Forecast Sales By Regions

7. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION TREATMENT MARKET ANALYSIS BY TREATMENT TYPE

  • 7.1. Overview By Treatment Type
  • 7.2. Historical and Forecast Data Analysis By Treatment Type
  • 7.3. Medication Historic and Forecast Sales By Regions
  • 7.4. Surgery Historic and Forecast Sales By Regions

8. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION TREATMENT MARKET ANALYSIS BY DRUGS

  • 8.1. Overview By Drugs
  • 8.2. Historical and Forecast Data Analysis By Drugs
  • 8.3. Serotonin-4 (5-Ht4) Receptor Agonist Historic and Forecast Sales By Regions
  • 8.4. Guanylate Cyclase-C Agonist Historic and Forecast Sales By Regions
  • 8.5. Laxatives Historic and Forecast Sales By Regions
  • 8.6. Stimulants Historic and Forecast Sales By Regions
  • 8.7. Others Historic and Forecast Sales By Regions

9. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION TREATMENT MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

  • 9.1. Overview By Route of Administration
  • 9.2. Historical and Forecast Data Analysis By Route of Administration
  • 9.3. Oral Historic and Forecast Sales By Regions
  • 9.4. Injectable Historic and Forecast Sales By Regions

10. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION TREATMENT MARKET ANALYSIS BY END-USERS

  • 10.1. Overview By End-Users
  • 10.2. Historical and Forecast Data Analysis By End-Users
  • 10.3. Hospitals Historic and Forecast Sales By Regions
  • 10.4. Homecare Historic and Forecast Sales By Regions
  • 10.5. Specialty Clinics Historic and Forecast Sales By Regions
  • 10.6. Others Historic and Forecast Sales By Regions

11. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION TREATMENT MARKET ANALYSIS BY DISTRIBUTION CHANNEL

  • 11.1. Overview By Distribution Channel
  • 11.2. Historical and Forecast Data Analysis By Distribution Channel
  • 11.3. Hospital Pharmacies Historic and Forecast Sales By Regions
  • 11.4. Retail Pharmacies Historic and Forecast Sales By Regions
  • 11.5. Others Historic and Forecast Sales By Regions

12. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION TREATMENT MARKET ANALYSIS BY GEOGRAPHY

  • 12.1. Regional Outlook
  • 12.2. Introduction
  • 12.3. North America Sales Analysis
    • 12.3.1 Overview, Historic and Forecast Data Sales Analysis
    • 12.3.2 North America By Segment Sales Analysis
    • 12.3.3 North America By Country Sales Analysis
    • 12.3.4 United States Sales Analysis
    • 12.3.5 Canada Sales Analysis
    • 12.3.6 Mexico Sales Analysis
  • 12.4. Europe Sales Analysis
    • 12.4.1 Overview, Historic and Forecast Data Sales Analysis
    • 12.4.2 Europe By Segment Sales Analysis
    • 12.4.3 Europe By Country Sales Analysis
    • 12.4.4 United Kingdom Sales Analysis
    • 12.4.5 France Sales Analysis
    • 12.4.6 Germany Sales Analysis
    • 12.4.7 Italy Sales Analysis
    • 12.4.8 Russia Sales Analysis
    • 12.4.9 Rest Of Europe Sales Analysis
  • 12.5. Asia Pacific Sales Analysis
    • 12.5.1 Overview, Historic and Forecast Data Sales Analysis
    • 12.5.2 Asia Pacific By Segment Sales Analysis
    • 12.5.3 Asia Pacific By Country Sales Analysis
    • 12.5.4 China Sales Analysis
    • 12.5.5 India Sales Analysis
    • 12.5.6 Japan Sales Analysis
    • 12.5.7 South Korea Sales Analysis
    • 12.5.8 Australia Sales Analysis
    • 12.5.9 South East Asia Sales Analysis
    • 12.5.10 Rest Of Asia Pacific Sales Analysis
  • 12.6. Latin America Sales Analysis
    • 12.6.1 Overview, Historic and Forecast Data Sales Analysis
    • 12.6.2 Latin America By Segment Sales Analysis
    • 12.6.3 Latin America By Country Sales Analysis
    • 12.6.4 Brazil Sales Analysis
    • 12.6.5 Argentina Sales Analysis
    • 12.6.6 Peru Sales Analysis
    • 12.6.7 Chile Sales Analysis
    • 12.6.8 Rest of Latin America Sales Analysis
  • 12.7. Middle East & Africa Sales Analysis
    • 12.7.1 Overview, Historic and Forecast Data Sales Analysis
    • 12.7.2 Middle East & Africa By Segment Sales Analysis
    • 12.7.3 Middle East & Africa By Country Sales Analysis
    • 12.7.4 Saudi Arabia Sales Analysis
    • 12.7.5 UAE Sales Analysis
    • 12.7.6 Israel Sales Analysis
    • 12.7.7 South Africa Sales Analysis
    • 12.7.8 Rest Of Middle East And Africa Sales Analysis

13. COMPETITIVE LANDSCAPE OF THE CHRONIC IDIOPATHIC CONSTIPATION TREATMENT COMPANIES

  • 13.1. Chronic Idiopathic Constipation Treatment Market Competition
  • 13.2. Partnership/Collaboration/Agreement
  • 13.3. Merger And Acquisitions
  • 13.4. New Product Launch
  • 13.5. Other Developments

14. COMPANY PROFILES OF CHRONIC IDIOPATHIC CONSTIPATION TREATMENT INDUSTRY

  • 14.1. Top Companies Market Share Analysis
  • 14.2. Market Concentration Rate
  • 14.3. ALLERGAN
    • 14.3.1 Company Overview
    • 14.3.2 Company Revenue
    • 14.3.3 Products
    • 14.3.4 Recent Developments
  • 14.4. Mallinckrodt Plc
    • 14.4.1 Company Overview
    • 14.4.2 Company Revenue
    • 14.4.3 Products
    • 14.4.4 Recent Developments
  • 14.5. Synergy Pharmaceuticals Inc
    • 14.5.1 Company Overview
    • 14.5.2 Company Revenue
    • 14.5.3 Products
    • 14.5.4 Recent Developments
  • 14.6. Shandong Luoxin Pharmaceutical Group Stock Co. Ltd
    • 14.6.1 Company Overview
    • 14.6.2 Company Revenue
    • 14.6.3 Products
    • 14.6.4 Recent Developments
  • 14.7. Takeda Pharmaceutical Company Limited
    • 14.7.1 Company Overview
    • 14.7.2 Company Revenue
    • 14.7.3 Products
    • 14.7.4 Recent Developments
  • 14.8. Sanofi
    • 14.8.1 Company Overview
    • 14.8.2 Company Revenue
    • 14.8.3 Products
    • 14.8.4 Recent Developments
  • 14.9. Zydus Cadila
    • 14.9.1 Company Overview
    • 14.9.2 Company Revenue
    • 14.9.3 Products
    • 14.9.4 Recent Developments
  • 14.10. Boehringer Ingelheim International GmbH
    • 14.10.1 Company Overview
    • 14.10.2 Company Revenue
    • 14.10.3 Products
    • 14.10.4 Recent Developments
  • 14.11. Shreya Life Sciences Pvt Ltd
    • 14.11.1 Company Overview
    • 14.11.2 Company Revenue
    • 14.11.3 Products
    • 14.11.4 Recent Developments
  • 14.12. Abbott
    • 14.12.1 Company Overview
    • 14.12.2 Company Revenue
    • 14.12.3 Products
    • 14.12.4 Recent Developments
  • 14.13. GSK Plc
    • 14.13.1 Company Overview
    • 14.13.2 Company Revenue
    • 14.13.3 Products
    • 14.13.4 Recent Developments
  • 14.14. Troikaa Pharmaceuticals Ltd
    • 14.14.1 Company Overview
    • 14.14.2 Company Revenue
    • 14.14.3 Products
    • 14.14.4 Recent Developments
  • 14.15. Lupin
    • 14.15.1 Company Overview
    • 14.15.2 Company Revenue
    • 14.15.3 Products
    • 14.15.4 Recent Developments
  • 14.16. East West Pharma
    • 14.16.1 Company Overview
    • 14.16.2 Company Revenue
    • 14.16.3 Products
    • 14.16.4 Recent Developments
  • 14.17. Ironwood Pharmaceuticals Inc
    • 14.17.1 Company Overview
    • 14.17.2 Company Revenue
    • 14.17.3 Products
    • 14.17.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies

LIST OF TABLES

  • Market Snapshot
  • Drivers: Impact Analysis
  • Restraints: Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • Analysis By Type (USD MN)
  • Normal-transit constipation Market Sales By Geography (USD MN)
  • Slow-transit constipation Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Analysis By Therapy Type (USD MN)
  • Pharmacological Therapy Market Sales By Geography (USD MN)
  • Non-pharmacological Therapy Market Sales By Geography (USD MN)
  • Analysis By Treatment Type (USD MN)
  • Medication Market Sales By Geography (USD MN)
  • Surgery Market Sales By Geography (USD MN)
  • Analysis By Drugs (USD MN)
  • Serotonin-4 (5-Ht4) Receptor Agonist Market Sales By Geography (USD MN)
  • Guanylate Cyclase-C Agonist Market Sales By Geography (USD MN)
  • Laxatives Market Sales By Geography (USD MN)
  • Stimulants Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Analysis By Route of Administration (USD MN)
  • Oral Market Sales By Geography (USD MN)
  • Injectable Market Sales By Geography (USD MN)
  • Analysis By End-Users (USD MN)
  • Hospitals Market Sales By Geography (USD MN)
  • Homecare Market Sales By Geography (USD MN)
  • Specialty Clinics Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Analysis By Distribution Channel (USD MN)
  • Hospital Pharmacies Market Sales By Geography (USD MN)
  • Retail Pharmacies Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Global Chronic Idiopathic Constipation Treatment Market Sales By Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United States Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate By Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • South East Asia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East & Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisition

LIST OF FIGURES

  • Research Scope of Chronic Idiopathic Constipation Treatment Report
  • Market Research Process
  • Market Research Methodology
  • Global Chronic Idiopathic Constipation Treatment Market Size, By Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis By Type
  • Market Attractiveness Analysis By Therapy Type
  • Market Attractiveness Analysis By Treatment Type
  • Market Attractiveness Analysis By Drugs
  • Market Attractiveness Analysis By Route of Administration
  • Market Attractiveness Analysis By End-Users
  • Market Attractiveness Analysis By Distribution Channel
  • Market Attractiveness Analysis By Region
  • Value Chain Analysis
  • Global Market Analysis By Type (USD MN)
  • Normal-transit constipation Market Sales By Geography (USD MN)
  • Slow-transit constipation Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Global Market Analysis By Therapy Type (USD MN)
  • Pharmacological Therapy Market Sales By Geography (USD MN)
  • Non-pharmacological Therapy Market Sales By Geography (USD MN)
  • Global Market Analysis By Treatment Type (USD MN)
  • Medication Market Sales By Geography (USD MN)
  • Surgery Market Sales By Geography (USD MN)
  • Global Market Analysis By Drugs (USD MN)
  • Serotonin-4 (5-Ht4) Receptor Agonist Market Sales By Geography (USD MN)
  • Guanylate Cyclase-C Agonist Market Sales By Geography (USD MN)
  • Laxatives Market Sales By Geography (USD MN)
  • Stimulants Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Global Market Analysis By Route of Administration (USD MN)
  • Oral Market Sales By Geography (USD MN)
  • Injectable Market Sales By Geography (USD MN)
  • Global Market Analysis By End-Users (USD MN)
  • Hospitals Market Sales By Geography (USD MN)
  • Homecare Market Sales By Geography (USD MN)
  • Specialty Clinics Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Global Market Analysis By Distribution Channel (USD MN)
  • Hospital Pharmacies Market Sales By Geography (USD MN)
  • Retail Pharmacies Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Global Market Sales (USD MN)
  • North America Market Sales (USD MN)
  • Europe Market Sales (USD MN)
  • Asia Pacific Market Sales (USD MN)
  • Latin America Market Sales (USD MN)
  • Middle East & Africa Market Sales (USD MN)
  • Recent Development in Industry
  • Top Company Market Share Analysis
  • Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.